DDInter1259 DDInter1835
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Nalidixic acid {u} (Compound) downregulates {v} (Gene) HTATSF1
HTATSF1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Nalidixic acid {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Nalidixic acid {u} (Compound) upregulates {v} (Gene) CNOT4
CNOT4 {u} (Gene) is downregulated by {v} (Compound) Topotecan
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Topotecan
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Nalidixic acid {u} (Compound) downregulates {v} (Gene) HTATSF1
HTATSF1 {u} (Gene) is regulated by {v} (Gene) SOX2
SOX2 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Nalidixic acid {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Nalidixic acid {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is regulated by {v} (Gene) TOP1
TOP1 {u} (Gene) is bound by {v} (Compound) Topotecan
Nalidixic acid {u} (Compound) upregulates {v} (Gene) CNOT4
CNOT4 {u} (Gene) is regulated by {v} (Gene) SRF
SRF {u} (Gene) is upregulated by {v} (Compound) Topotecan
Nalidixic acid (Compound) downregulates HTATSF1 (Gene) and HTATSF1 (Gene) is upregulated by Topotecan (Compound)
Nalidixic acid (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Topotecan (Compound)
Nalidixic acid (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is downregulated by Topotecan (Compound)
Nalidixic acid (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Topotecan (Compound)
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Nalidixic acid (Compound) downregulates HTATSF1 (Gene) and HTATSF1 (Gene) is regulated by SOX2 (Gene) and SOX2 (Gene) is upregulated by Topotecan (Compound)
Nalidixic acid (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Nalidixic acid (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is regulated by TOP1 (Gene) and TOP1 (Gene) is bound by Topotecan (Compound)
Nalidixic acid (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is regulated by SRF (Gene) and SRF (Gene) is upregulated by Topotecan (Compound)